
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing lamotrigine, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing lamotrigine are listed in suspension, tablet and tablet for suspension forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Lamotrigine is an anticonvulsant prescription medicine; compounded preparations include oral suspensions, which require a prescription and are not FDA-approved.
Lamotrigine is an anticonvulsant of the triazine class. Laboratory studies suggest it inhibits voltage-sensitive sodium channels, which stabilizes nerve cell membranes and reduces release of excitatory signaling chemicals such as glutamate; its exact mechanism in people is not known. Manufactured products include Lamictal tablets, tablets for oral suspension and orally disintegrating tablets, Lamictal XR extended-release tablets, and generic versions. Lamictal is FDA-approved as add-on therapy for partial-onset seizures, primary generalized tonic-clonic seizures and seizures of Lennox-Gastaut syndrome, for conversion to single-drug therapy in certain adults with partial-onset seizures, and for maintenance treatment of bipolar I disorder. A prescriber may order lamotrigine compounded when a patient needs a liquid form; US Pharmacist has published a compounded oral suspension formulation. Compounded preparations are not FDA-approved and require a prescription.
Lamictal carries a boxed warning for serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, which can be life threatening. The risk is higher in children, with valproate, when the starting dose or dose increases go beyond the label's schedule, and in people who carry the HLA-B*1502 gene variant. Call your prescriber right away about any rash, fever, swollen glands or mouth sores. The label also warns of HLH (a life-threatening immune reaction), multiorgan hypersensitivity, blood disorders, suicidal thoughts, aseptic meningitis and heart rhythm problems in people with structural heart disease. Estrogen-containing birth control can lower lamotrigine levels. Do not stop it suddenly, because seizures can occur. People allergic to lamotrigine should not take it. If you are pregnant or planning pregnancy, talk to your prescriber. Lamotrigine passes into breast milk; LactMed advises watching infants for apnea, rash, drowsiness or poor sucking. For side effects, talk to your prescriber or pharmacist.
Proposed mechanism: inhibition of voltage-sensitive sodium channels with reduced presynaptic glutamate and aspartate release. In vitro, lamotrigine shows Class IB antiarrhythmic activity; the Lamictal label warns that it could widen QRS and induce proarrhythmia in patients with clinically important structural or functional heart disease, and that other sodium channel blockers may add to this risk. Oral absorption is rapid and complete (absolute bioavailability 98%), plasma protein binding is about 55%, and clearance is mainly by glucuronidation to an inactive 2-N-glucuronide. Valproate raises lamotrigine concentrations; carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir, atazanavir/ritonavir and estrogen-containing oral contraceptives lower them. StatPearls advises against combining with dofetilide. Labeled indications (Lamictal): adjunctive therapy for partial-onset, PGTC and Lennox-Gastaut seizures, conversion to monotherapy, and bipolar I maintenance; it is not recommended for acute manic or mixed episodes. StatPearls describes off-label uses such as bipolar depression; these are not FDA-approved indications. Titration and dosing per prescriber, following the label's escalation schedule to limit rash risk; taper on discontinuation. The boxed warning lists the HLA-B*1502 allele as a risk factor for serious rash. The label warns of medication errors from name confusion and between formulations. Monitor for rash, hypersensitivity, HLH, blood dyscrasias, mood and suicidality, and breastfed infants.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally